Drilldown: Medicines

None (2) · Hydroxychloroquine (1)

Ajovy (1) · Emgality (1) · Plaquenil; mostly prescribed generically (1)

Anti-CGRP ligand monoclonal antibody (2) · [[:Category:Antimalarials|Antimalarial (4-aminoquinoline)]] (1) · [[:Category:DMARDs|DMARD]] (1) · [[:Category:Immunomodulators|Immunomodulator]] (1)

None (1) · Humanized IgG2 monoclonal antibody binding both isoforms of CGRP peptide (1) · Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1)

Preventive treatment of migraine in adults (episodic and chronic) (1) · Preventive treatment of migraine in adults; episodic cluster headache (1) · '"`UNIQ--vote-000007E7-QINU`"', '"`UNIQ--vote-000007E8-QINU`"', '"`UNIQ--vote-000007E9-QINU`"', '"`UNIQ--vote-000007EA-QINU`"', '"`UNIQ--vote-000007EB-QINU`"' (1)

200-400 mg PO daily; '''dose by actual body weight ≤5 mg/kg/d''' to reduce retinopathy risk (AAO 2016 guideline) (1) · 225 mg SC monthly, or 675 mg SC every 3 months (quarterly) (1) · Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1)

120 mg/mL prefilled syringe or autoinjector (1) · 200 mg tablets; 100 mg/5 mL suspension (1) · 225 mg/1.5 mL prefilled syringe or autoinjector (1)

240 mg loading + 120 mg/month for migraine; 300 mg/month for cluster (1) · 400 mg/d typical maintenance; weight-adjusted ceiling per ophthalmology guidance (1) · 675 mg/quarter (1)

Oral (1) · Subcutaneous (2)

None · Hours · 30-60 minutes · 1-2 hours · ~30 min · LDL lowering at 2 weeks, max by 4 weeks · ~1 hour · 15-30 minutes · 15–30 min · 1–2 h · 30–60 min · Antidepressant effect emerges over 1-2 weeks · BP and symptomatic LUTS improvement within 1-2 weeks · BP effect within 1-2 weeks · Clinical improvement within 24-72 hours · Days · Motor improvement over days at therapeutic dose · Over weeks · Postprandial glucose effect within days; HbA1c by 12 weeks · Sleep effect from first dose; antidepressant effect over 1-4 weeks

Other values:

Search

Monthly dosing (1) · Monthly or quarterly dosing (1) · Weeks (long half-life) (1)

~27 days (1) · ~31 days (1) · ~40 days (terminal; reflects extensive tissue distribution)'"`UNIQ--ref-000007EC-QINU`"' (1)

70-75% (oral)'"`UNIQ--ref-000007ED-QINU`"' (1) · Not formally established (1) · Not formally established (high SC) (1)

Limited data; avoid (2) · Long-considered safe in pregnancy for lupus and other rheumatologic indications; benefits typically outweigh.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

Rx (2) · [[USLegal:Prescription only|Rx-only]] in US (1)